Inclusion Criteria:  This study will only include participants who were enrolled in the FIGARO-DKD study (NCT02545049) and had received up to 20 mg finerenone or placebo for ≥24 months. For each participant, pharmacokinetic (PK) plasma samples from Visit 3 and at least 2 other Visits (Visit 5, Visit 8, Visit 11) must be available on storage from the main study FIGARO-DKD.  Exclusion Criteria:  Participants which did not show overall compliance of 80 to 120% with study intervention in FIGARO-DKD. Participants which were not part of the full analysis set (FAS) of FIGARO-DKD. Participants with known fatal outcome. Participants with baseline estimated glomerular filtration rate (eGFR) ≤25 mL/min/1.73m^2. Participants with low baseline risk (normal albuminuria and eGFR≥60 mL/min/1.73m^2). Sponsor request (after discussion with the investigator), for reasons such as a significant protocol deviation.